Mergers & Acquisitions - Mergers & Acquisitions, Generics, Oncology

Filter

Cipla links with Hetero for biosimilar Aranesp; M&A in Yemen

30-06-2014

Cipla has collaborated with fellow Indian drugmaker Hetero to launch a biosimilar of the drug darbepoetin…

ActoriseAmgenAranespBiosimilarsCiplaGenericsHeteroIndiaMarkets & MarketingMergers & AcquisitionsOncologyRest of the World

Cipla prevails in Sutent patent dispute with Pfizer; puts hold on Cipla Medpro deal

12-02-2013

The Indian patent office has again ruled in favor of domestic drugmaker Cipla (BSE: 500087), reinstating…

Asia-PacificCiplaCipla MedproGenericsLegalMergers & AcquisitionsOncologyPatentsPfizerRest of the WorldSutent

Aduro BioTech buys all GVAX assets from BioSante; Aspen in talks to buy Merck unit

05-02-2013

Aduro BioTech, a privately-held, US venture capital backed biotechnology company, says it has acquired…

Aduro BioTechAspen PharmacareBioSante PharmaceuticalsBiotechnologyGenericsGVAXImmunologicalsMerck & CoMergers & AcquisitionsOncologyVaccines

Takeda sells non-Colcrys URL Pharma generic business to Sun Pharma; Eisai divests Gliadel Wafer in USA

17-12-2012

Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502), has entered into a definitive agreement…

Arbor PharmaceuticalsColcrysEisaiGenericsGliadelMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalSun Pharmaceutical IndustriesTakeda PharmaceuticalsURL Pharma

GlaxoSmithKline pulls sNDA for Tykerb plus Herceptin; Watson/Actavis update

13-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New…

ActavisGenericsGlaxoSmithKlineHerceptinMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRegulationRocheTykerbWatson Pharmaceuticals

Back to top